Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

被引:169
|
作者
Sieber, Martin A. [1 ]
Lengsfeld, Philipp [2 ]
Frenzel, Thomas [1 ]
Golfier, Sven [1 ]
Schmitt-Willich, Heribert [3 ]
Siegmund, Fred [4 ]
Walter, Jakob [4 ]
Weinmann, Hanns-Joachim [1 ]
Pietsch, Hubertus [1 ]
机构
[1] Bayer Schering Pharma AG, TRG Diagnost Imaging, D-13353 Berlin, Germany
[2] Bayer Schering Pharma AG, GMA DG Diagnost Imaging, D-13353 Berlin, Germany
[3] Bayer Schering Pharma AG, GDD Diagnost Imaging, D-13353 Berlin, Germany
[4] Bayer Schering Pharma AG, Nonclin Drug Safety, D-13353 Berlin, Germany
关键词
gadolinium; nephrogenic systemic fibrosis; contrast agents; stability; macrocyclic;
D O I
10.1007/s00330-008-0977-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Recent reports suggest that nephrogenic systemic fibrosis (NSF) is associated with the administration of gadolinium (Gd)-based contrast agents (GBCAs) and in particular with the stability of the Gd-complex. The aim of this investigation was to compare GBCAs and their potential to trigger NSF. Forty-two healthy male rats received repeated intravenous injections of six different GBCAs at high doses to simulate the exposure seen in patients with severe renal dysfunction. Histopathological and immunohistochemical analysis of the skin was performed, and the concentrations of Gd, zinc and copper were measured in several tissues by inductive coupled plasma atomic emission spectroscopy. Macroscopic and histological skin changes similar to those seen in NSF patients were only observed in rats receiving Omniscan. In addition, very high concentrations of Gd were observed in the animals treated with Omniscan, and, to a lesser extent, in animals treated with OptiMARK. Significantly lower levels of Gd were found after the treatment with ionic linear agents and even less after the treatment with macrocyclic agents. The data in this investigation strongly suggest that the stability of the Gd-complex is a key factor for the development of NSF-like symptoms in this experimental setting.
引用
收藏
页码:2164 / 2173
页数:10
相关论文
共 36 条
  • [1] Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions
    Martin A. Sieber
    Philipp Lengsfeld
    Thomas Frenzel
    Sven Golfier
    Heribert Schmitt-Willich
    Fred Siegmund
    Jakob Walter
    Hanns-Joachim Weinmann
    Hubertus Pietsch
    European Radiology, 2008, 18 : 2164 - 2173
  • [2] Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
    Abu-Alfa, Ali K.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2011, 18 (03) : 188 - 198
  • [3] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Penfield, Jeffrey G.
    PEDIATRIC NEPHROLOGY, 2008, 23 (12) : 2121 - 2129
  • [4] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Jeffrey G. Penfield
    Pediatric Nephrology, 2008, 23 : 2121 - 2129
  • [5] Nephrogenic systemic fibrosis and gadolinium-based contrast media
    Andrejak, Michel
    Thuillier, Delphine
    Lok, Catherine
    Gras-Champel, Valerie
    THERAPIE, 2007, 62 (02): : 169 - 172
  • [6] Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue
    Wiginton, Clark D.
    Kelly, Brent
    Oto, Aytekin
    Jesse, Mary
    Aristimuno, Patricia
    Ernst, Randy
    Chaljub, Gregory
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2008, 190 (04) : 1060 - 1068
  • [7] Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis
    Heverhagen, J. T.
    Krombach, G. A.
    Gizewski, E.
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2014, 186 (07): : 661 - 669
  • [8] Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents
    Semelka, Richard C.
    Prybylski, John P.
    Ramalho, Miguel
    MAGNETIC RESONANCE IMAGING, 2019, 58 : 174 - 178
  • [9] Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis
    Ersoy, Hale
    Rybicki, Frank J.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2007, 26 (05) : 1190 - 1197
  • [10] Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents - A status
    Heinrich, M.
    Uder, M.
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2007, 179 (06): : 613 - 617